BioWorld Asia

Jan. 9, 2008

Addex, Merck Ink $702M Deal for Schizophrenia Compound

Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International) Read More

NicOx Renews Research Deal with Pfizer in Ophthalmology

Gene Variant Could Provide Clues to the Cause of ALS

Silence Tries to Calm Investors After Share Price Takes a Dive

EMA Promises to Boost Professionalism in 2008

Faust Signs Research Deal with Takeda for GPCRs

Sepracor Enters $175M Deal with Bial for Epilepsy Drug

Biotech Industry Welcomes EU Support for its Products

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...